Provectus Biopharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, and XenoTech, a preclinical CRO and pioneer in collaborative research surrounding in vitro drug metabolism and pharmacokinetics services, today announced that an article describing a study to determine the potential of rose bengal disodium ... (more)
http://ift.tt/1mSyexX
http://ift.tt/1mSyexX
No comments:
Post a Comment